hCLK2: A Protein Target Or Biomarker for Disease? (G9894)
hCLK2: A Protein Target Or Biomarker for Disease?
TELO2 (hCLK2) is a protein that is expressed in various tissues of the body, including the brain. It is a key regulator of the heart rate and has been linked to a number of neurological and cardiovascular diseases. In recent years, researchers have been interested in studying hCLK2 as a potential drug target or biomarker for a number of conditions, including heart failure, hypertension, and cancer.
One of the key challenges in studying hCLK2 is its complex structure. hCLK2 is a 21-kDa protein that consists of an N-terminal alpha-helix, a catalytic alpha-helices, and a C-terminal T-loop. It has a number of unique features that make it difficult to study, including a long N-terminal tail that can interact with other proteins, a flexibility in its alpha-helices that allows it to adopt different conformations, and a propensity to undergo conformational changes that can affect its function.
Despite these challenges, researchers have been able to study hCLK2 using a variety of techniques, including biochemical, cellular, and structural studies. One of the most promising approaches to studying hCLK2 is the use of small molecule inhibitors, which can be used to modulate its activity and determine its potential as a drug.
One of the most well-studied small molecule inhibitors of hCLK2 is the drug bona fide, which is a compound that binds to the N-terminal region of hCLK2 and inhibits its activity. bona fide has been shown to be effective in animal models of hypertension and heart failure, and it is currently being tested in clinical trials for these conditions.
Another small molecule inhibitor of hCLK2 is the drug geometric channel, which is a compound that binds to the T-loop region of hCLK2 and inhibits its activity. geometric channel has also been shown to be effective in animal models of heart failure and has been tested in clinical trials for this condition.
In addition to small molecule inhibitors, researchers are also interested in studying hCLK2 as a potential biomarker for a number of conditions. One of the key advantages of hCLK2 is its expression is highly sensitive to changes in heart rate, which makes it an attractive candidate for use as a marker for cardiac function.
Research has also shown that hCLK2 is expressed in a number of tissues that are commonly affected by a variety of diseases, including heart failure, hypertension, and cancer. This makes it an attractive candidate for use as a biomarker for these conditions. For example, studies have shown that hCLK2 is expressed in the hearts of dogs that have developed heart failure, and that it is decreased in the hearts of dogs that have developed hypertension.
Another promising approach to studying hCLK2 as a biomarker is the use of computational tools, such as mass spectrometry, to identify changes in hCLK2 expression that are associated with disease. This approach has been used to identify changes in hCLK2 expression in a variety of diseases, including heart failure and cancer.
Overall, hCLK2 is a protein that has the potential to be a valuable drug target or biomarker for a variety of conditions. Its unique structure and complex function make it difficult to study, but the use of small molecule inhibitors and computational tools has shown that it is possible to study its activity and potential as a drug or biomarker. Further research is needed to fully understand the role of hCLK2 in disease and to develop effective treatments.
Protein Name: Telomere Maintenance 2
Functions: Regulator of the DNA damage response (DDR). Part of the TTT complex that is required to stabilize protein levels of the phosphatidylinositol 3-kinase-related protein kinase (PIKK) family proteins. The TTT complex is involved in the cellular resistance to DNA damage stresses, like ionizing radiation (IR), ultraviolet (UV) and mitomycin C (MMC). Together with the TTT complex and HSP90 may participate in the proper folding of newly synthesized PIKKs. Promotes assembly, stabilizes and maintains the activity of mTORC1 and mTORC2 complexes, which regulate cell growth and survival in response to nutrient and hormonal signals. May be involved in telomere length regulation
The "TELO2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TELO2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
Telomerase holoenzyme complex | TEN1 | TEN1-CDK3 | Teneurin | TENM1 | TENM2 | TENM2-AS1 | TENM3 | TENM3-AS1 | TENM4 | TENT2 | TENT4A | TENT4B | TENT5A | TENT5B | TENT5C | TENT5C-DT | TENT5D | TEP1 | TEPP | TEPSIN | TERB1 | TERB2 | TERC | TERF1 | TERF1P3 | TERF2 | TERF2IP | TERLR1 | TERT | TES | TESC | TESK1 | TESK2 | TESMIN | TESPA1 | TET1 | TET2 | TET2-AS1 | TET3 | Tetraspanin | TEX10 | TEX101 | TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF | TFAM | TFAMP1 | TFAP2A | TFAP2A-AS1 | TFAP2A-AS2 | TFAP2B | TFAP2C | TFAP2D | TFAP2E | TFAP4 | TFB1M | TFB2M | TFCP2 | TFCP2L1 | TFDP1 | TFDP1P2 | TFDP2 | TFDP3 | TFE3
